** Shares of Prescient Therapeutics PTX.AX rise as much as 28.6% to A$0.054, hit their highest levels since February 11
** The clinical-stage oncology co says it received the US FDA Fast-Track designation for PTX-100, a treatment for adults with relapsed or refractory mycosis fungoides
** PTX-100 is a compound with the ability to block an important cancer growth enzyme, says co
** The fast-track status is an important step towards commercialisation of the drug, says co
** About 2.7 million shares change hands, 4.3 times the 30-day average volume of shares
** Stock down 16% this year, as of last close
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。